Full-Dose Heparin Benefit in Certain COVID-19 Patients Confirmed | MedPage Today
Cerebral Venous Thrombosis in Patients With Heparin-Induced Thrombocytopenia a Systematic Review | Stroke
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis - The Lancet Haematology
Anticoagulant activity and pleiotropic effects of heparin - ScienceDirect
Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial - The Lancet
High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy - Journal of Allergy and Clinical Immunology
Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis | The BMJ
Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction | Circulation: Cardiovascular Interventions
Medicines from Germany - Heparin-ratiopharm 60 000 ointment, 100 g
Anticoagulant activity and pleiotropic effects of heparin - ScienceDirect
Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate | tctmd.com
Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease - Kidney International
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial - The Lancet
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial | The BMJ
Bivalirudin Versus Heparin Monotherapy in ST-Segment–Elevation Myocardial Infarction | Circulation: Cardiovascular Interventions
Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn't | tctmd.com
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial - The Lancet Haematology
Anticoagulant activity and pleiotropic effects of heparin - ScienceDirect
Heparin-Induced Thrombocytopenia | NEJM
Risk of mortality drops in COVID-19 patients given anticoagulation within a day of hospital admission, research finds - The Pharmaceutical Journal
Swiss Medical Weekly - Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland
Aspirin™ – Surprisingly Versatile | Bayer global
HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients | tctmd.com
Anticoagulant activity and pleiotropic effects of heparin - ScienceDirect
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial - The Lancet Haematology
The identification and management of heparin-induced thrombocytopenia in the vascular patient - Journal of Vascular Surgery
Stroke - News, Articles etc. - European Pharmaceutical Review
